US00214Q3020 - ARKG (BATS)
ARK GENOMIC REVOLUTION ETF ETF
23,67 USD
Current Prices from ARK GENOMIC REVOLUTION ETF
Exchange | Ticker | Currency | Last Trade | Price | Daily Change | Daily Change % |
---|---|---|---|---|---|---|
NYSE |
ARKG
|
USD
|
21.12.2024 00:10
|
23,67 USD
| 22,93 USD | 3,23 % |
Performance
Day | Week | Month | 3 Months | 6 Months | 1 Year | 5 Years |
---|---|---|---|---|---|---|
0,00 % | -4,01 % | 1,61 % | -9,98 % | -2,87 % | -26,12 % | -33,70 % |
Asset Allocation
Asset | Percentage % |
---|---|
Stock US | 88,40 % |
Stock non-US | 11,39 % |
Cash | 0,20 % |
NotClassified | 0,00 % |
Other | 0,00 % |
Bond | 0,00 % |
Largest Positions
Symbol | ISIN | Name | Percentage % |
---|---|---|---|
TDOC | Teladoc Health Inc | 6,78 % | |
FATE | Fate Therapeutics Inc | 4,79 % | |
EXAS | Exact Sciences Corporation | 4,71 % | |
PACB | Pacific Biosciences of California Inc | 4,65 % | |
VRTX | Vertex Pharmaceuticals Incorporated | 4,42 % | |
IONS | Ionis Pharmaceuticals Inc | 4,27 % | |
REGN | Regeneron Pharmaceuticals Inc | 3,92 % | |
CDNA | CareDx Inc | 3,28 % | |
TAK | Takeda Pharmaceutical Company Limited | 2,97 % | |
TWST | Twist Bioscience Corporation | 2,91 % |
Region Distribution
Region | Percentage % |
---|---|
North America | 89,76 % |
Europe Developed | 6,89 % |
Japan | 2,95 % |
Africa/Middle East | 0,41 % |
Asia Developed | 0,00 % |
Asia Emerging | 0,00 % |
Australasia | 0,00 % |
Europe Emerging | 0,00 % |
Latin America | 0,00 % |
United Kingdom | 0,00 % |
Sector Distribution
Sector | Percentage % |
---|---|
Gesundheitswesen | 94,90 % |
Technologie | 2,53 % |
Finanzdienstleistungen | 1,74 % |
Grundstoffe | 0,48 % |
Basiskonsumgüter | 0,35 % |
Verbrauchsgüter | 0,00 % |
Immobilien | 0,00 % |
Telekommunikation | 0,00 % |
Energie | 0,00 % |
Industrieunternehmen | 0,00 % |
Company Profile for ARK GENOMIC REVOLUTION ETF ETF
The fund is an actively-managed exchange-traded fund ("ETF") that will invest under normal circumstances primarily (at least 80% of its assets) in domestic and foreign equity securities of companies across multiple sectors, including healthcare, information technology, materials, energy and consumer discretionary, that are relevant to the fund's investment theme of the genomics revolution ("Genomics Revolution Companies"). It is non-diversified.
Fund Master Data
Issuer Ark Financial
Asset Class ETF
Name ARK Genomic Revolution ETF
Fund Currency USD
Category Health
Payout NA
fund.
Morningstar Rating 5
Fund Key Figures
Fund Size 9,74 M EUR
Investment Strategy
The investment seeks long-term growth of capital. The fund is an actively-managed exchange-traded fund (ETF) that will invest under normal circumstances primarily (at least 80% of its assets) in domestic and foreign equity securities of companies across multiple sectors, including healthcare, information technology, materials, energy and consumer discretionary, that are relevant to the fund's investment theme of the genomics revolution (Genomics Revolution Companies). It is non-diversified.
Company Data to ARK GENOMIC REVOLUTION ETF ETF
Name ARK GENOMIC REVOLUTION ETF
Company ARK Genomic Revolution ETF
Symbol ARKG
Primary Exchange
BATS
ISIN US00214Q3020
Asset Class ETF
Sector Financial Services
Industry Asset Management
Market Capitalization 1 Mrd.
Country United States of America
Currency USD
Employees -
IPO Date 2014-10-31
Dividends from 'ARK GENOMIC REVOLUTION ETF'
Ex-Date | Dividend per Share |
---|---|
29.12.2021 | 0,38 USD |
29.12.2020 | 0,79 USD |
27.12.2019 | 1,05 USD |
27.12.2018 | 0,47 USD |
27.12.2017 | 0,33 USD |
Ticker Symbols
Name | Symbol |
---|---|
NYSE | ARKG |
More Shares
Investors who ARK GENOMIC REVOLUTION ETF hold also have the following shares in their portfolio:
The financial platform MoneyPeak tracks and analyzes investments and portfolios.
From securities portfolios to crypto purchases.
Useful, simple, and free. Stocks, ETFs, ETCs, ETNs, indices, funds, bonds, certificates, currencies, options, rights issue.
Useful, simple, and free. Stocks, ETFs, ETCs, ETNs, indices, funds, bonds, certificates, currencies, options, rights issue.